secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038576
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE
--------------------------------------------------------------------------------

- Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.
- Cemsidomide Phase 1 MM data: ORR 40% at 75 µg and 50% at 100 µg; well-tolerated; highest dose 100 µg.
- Productive Type C meeting with FDA; registrational development expected to start early 2026; full data at IMS September 2025.
- Cash $223M as of June 30, 2025; runway extended to mid-2027.
- Preclinical milestone achieved under Merck KGaA collaboration; $1M earned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/0001628280-25-038576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/cccc-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer